Displaying drugs 9476 - 9500 of 9612 in total
Exisulind
Investigational
Lestaurtinib
Investigational
Xaliproden
Investigational
NPS-2143
Investigational
XL228
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
Arylacenamide
Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
Investigational
Plinabulin
Investigational
ATL-2502
ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
Investigational
AV-412
Investigational
NV-07a
NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Investigational
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Canertinib
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Fradafiban
Investigational
Opaganib
Opaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.
Investigational
Dociparstat sodium
Investigational
Abafungin
Investigational
ENMD-1198
Investigational
Cariporide
Investigational
TBC-3711
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
SNS-032
Investigational
Zenarestat
Experimental
alpha-Conotoxin VC 1.1
Investigational
G4460
Investigational
Vasomera
Investigational
Displaying drugs 9476 - 9500 of 9612 in total